河北医科大学学报

• 论著 • 上一篇    下一篇

新型口服抗凝药治疗静脉血栓栓塞症的效果及安全性的Meta分析

  

  1. 重庆医科大学附属第二医院呼吸内科,重庆 400010
  • 出版日期:2019-03-25 发布日期:2019-03-20
  • 作者简介:胡天洋(1992-),男,四川资阳人,重庆医科大学附属第二医院医学硕士研究生,从事呼吸系统疾病诊治研究。

Efficacy and safety of nonvitamin K antagonist oral anticoagulants for venous thromboembolism:a Metaanalysis

  1. Department of Respiration, the Second Affiliated Hospital of Chongqing Medical University, Chongqing  400010, China
  • Online:2019-03-25 Published:2019-03-20

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察非维生素K拮抗剂新型口服抗凝药治疗静脉血栓栓塞症的效果及安全性。
〖HTH〗方法〖HTSS〗〖KG*2〗计算机检索PubMed、Cochrane Library、EMbase数据库中新型口服抗凝药与维生素K拮抗剂对比治疗静脉血栓栓塞症的随机对照试验及多中心对照研究相关文献,检索日期截至2017年6月,应用RevMan 5.3 软件对数据进行Meta分析。
〖HTH〗结果〖HTSS〗〖KG*2〗纳入7个研究共计29 879例患者, 结果显示:①新型口服抗凝药较传统维生素K拮抗剂可明显降低大出血事件(OR=0.61,95%CI=0.50~0.75,P<001)、致命性出血事件(OR=0.37,95%CI=0.17~0.81,P=0.01)发生的风险;②新型口服抗凝药与传统维生素K拮抗剂相比,复发性静脉血栓栓塞症或静脉血栓栓塞症相关的死亡发生率差异无统计学意义(OR=0.94,95%CI=0.81~1.08,P=0.38),全因死亡率差异无统计学意义(OR=097,95%CI=0.83~1.13,P=0.70);③纳入研究所报道的不良反应结果无法合并分析,新型口服抗凝药的安全性优势有待进一步评估。
〖HTH〗结论〖HTSS〗〖KG*2〗新型口服抗凝药治疗静脉血栓栓塞症的效果不亚于传统维生素K拮抗剂,在降低出血风险方面前者更具优势,但其安全性优势仍需进一步评估。

关键词: 静脉血栓栓塞, 抗凝药, Meta分析

Abstract: [Abstract] Objective〖HTSS〗〓To evaluate the efficacy and safety of nonvitamin K antagonist oral anticoagulants in treating venous thromboembolism.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Data of randomized controlled trials and multicenter controlled studies about nonvitamin K antagonist oral anticoagulants versus vitamin K antagonists for treating venous thromboembolism were searched from PubMed, Cochrane Library and EMbase until June 2017, and data were analyzed by RevMan 5.3 software.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓A total of 29 879 patients were included in 7 studies, Metaanalysis showed that: ① Compared with traditional vitamin K antagonists, the new oral nonvitamin K antagonist anticoagulants could significantly reduce major bleeding events (OR=0.61, 95%CI=0.50-0.75,P<0.01) and fatal bleeding events(OR=0.37, 95%CI=0.17-0.81, P=0.01). ②nonvitamin K antagonist oral anticoagulants could not reduce the incidence of recurrent venous thromboembolism or venous thromboembolismrelated death(OR=0.94, 95%CI=0.81-0.18, P=0.38)or allcause mortality(OR=0.97,95%CI=0.83-1.13,P=0.70)compared with vitamin K antagonists. ③The results of adverse events can not be combined and analyzed,the safety superiority of nonvitamin K antagonist oral anticoagulants needs to be further evaluated.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The efficacy of nonvitamin K antagonist oral anticoagulants in treating venous thromboembolism is no less than that of traditional vitamin K antagonists, and the former could reduce bleeding events significantly though their safety superiority needs to be further evaluated.

Key words: venous thromboembolism; anticoagulants; , Metaanalysis